Table 1.
Attributes and levels of fictitious prostate cancer screening programs
| Attributes | Attribute label used in survey | Attribute supplementary information | Levels | Opt-out option level | References |
|---|---|---|---|---|---|
| Mortality by prostate cancer | Number of deaths by prostate cancer |
2 / 1000a 5 / 1000a 6 / 1000a |
6 / 1000 | Schröder et al.(2014) [3] | |
| False positive result | Number of false positive results to the screening test (false alarm) | This wrong alert induces potentially useless supplementary exams (biopsies) because men do not have cancer |
50 / 1000a 150 / 1000a 250/ 1000a |
0 | Kipeläinen, et al. (2011) [25] |
| False negative result | Number of false negative results on screening test | Prostate cancer is undetected yet individual has prostate cancer |
1 / 1000 5 / 1000 10 / 1000 |
0 | Verbeek, et al. (2018) [24] |
| Overdiagnosis | Number of prostate cancers detected, even treated unnecessarily (overdiagnosis) | This prostate cancer would never cause symptoms, pain or death |
10 / 1000a 30 / 1000a 50 / 1000a |
0 | Etzioni, et al. (2013) [22] |
| Recommended frequency | Frequency at which you should be screened |
Every year Every 2 years Every 4 years |
NA | Tsodikov et al. (2017) [2] | |
| Out-of-pocket costs | Amount to pay for each screening session | Amount is not reimbursed by national health insurance or supplementary health insurance |
0 € 10 € 20 € 40 € |
0 | NABM [1], NGAP [2] |
Notes: aper one thousand men regularly screened for prostate cancer
(1)http://www.codage.ext.cnamts.fr/codif/nabm/index_presentation.php?p_site=AMELI
(2)https://www.ameli.fr/sites/default/files/Documents/377680/document/ngap_14.04.18.pdf